Jan 24, 2020
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
Jan 23, 2020
CStone successfully hosted the first U.S. R&D Day in New York
Jan 08, 2020
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma
Jan 06, 2020
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Dec 12, 2019
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Dec 10, 2019
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
Dec 09, 2019
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Dec 06, 2019
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
Nov 19, 2019
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib
Nov 06, 2019
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Sep 21, 2019
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab
Sep 20, 2019
2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors
Sep 19, 2019
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
Aug 26, 2019
CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST
Aug 22, 2019
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
Aug 22, 2019
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
Aug 19, 2019
Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress
Aug 15, 2019
CStone Pharmaceuticals Reports First Half 2019 Financial Results
Aug 13, 2019
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
Aug 07, 2019
CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park